Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692879 | 0.84 | MEN1 (0.46) | ALDH1A1USP2TSHRLMNAHTT | |
| SCHEMBL16472474 | 0.83 | HDAC7 (0.34) | ALDH1A1TSHRLMNAS1PR1S1PR3 | |
| SCHEMBL9735094 | 0.81 | LMNA (0.38) | ALDH1A1USP2LMNACNR2 | |
| SCHEMBL10296844 | 0.81 | LMNA (0.38) | ALDH1A1USP2LMNACNR2 | |
| SCHEMBL10296842 | 0.81 | LMNA (0.38) | ALDH1A1USP2LMNACNR2 | |
| SCHEMBL11284773 | 0.80 | ALDH1A1 (0.43) | ALDH1A1USP2TSHRLMNAHTT | |
| SCHEMBL17122532 | 0.79 | TSHR (0.34) | ALDH1A1USP2TSHRHTT | |
| SCHEMBL19343056 | 0.78 | HPGD (0.43) | ALDH1A1HTT | |
| SCHEMBL9736488 | 0.78 | KDM4E (0.42) | TSHRS1PR1S1PR3 | |
| SCHEMBL16083130 | 0.78 | KDM4E (0.42) | TSHRS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976512-B1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8003800-B2 | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-8003800-B2 | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2007080542-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | S1PR3, S1PR1, S1PR2 | ALDH1A1 1713/4885USP2 4511/4885TSHR 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.